TennesseeSB 0282114th General Assembly (2025-2026)SenateWALLET

AN ACT to amend Tennessee Code Annotated, Title 53 and Title 63, relative to medical treatment.

Sponsored By: Sponsor information unavailable

Signed by Governor

Health Care

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Bill Overview

Analyzed Economic Effects

5 provisions identified: 3 benefits, 2 costs, 0 mixed.

Severely ill patients gain personalized treatment access

Beginning July 1, 2025, patients with life-threatening or severely debilitating illnesses can request experimental drugs, biological products, or devices made only for them using their genetic profile. A doctor must confirm the illness, review all FDA-approved options with the patient, recommend treatment, and document eligibility. Treatment must come through a facility operating under Federalwide Assurance rules for protecting human research subjects. Written consent must identify the treatment, explain approved options, state that conventional treatments are unlikely to prolong life, and describe possible outcomes, worst-case risks, and likely side effects; the patient—or a guardian or attorney-in-fact for a minor—must sign, with the doctor and a witness attesting. Tennessee officials cannot block or attempt to block access, but licensed providers can give advice that follows medical standards.

Patients face no guaranteed treatment coverage

Beginning July 1, 2025, insurers, health plans, plan administrators, and government agencies can cover personalized experimental treatment and related services, but this law does not require payment. Facilities and manufacturers can offer treatment free or charge treatment and manufacturing costs. Manufacturers do not have to supply treatment, and providers do not have to supply services unless they approve the request. Required consent warns that coverage is not guaranteed without a legal or contract duty, and patients bear expenses unless another agreement says otherwise. It also warns that seeking treatment aimed at a cure may affect hospice eligibility.

Heirs protected from unpaid treatment debt

Beginning July 1, 2025, heirs are not liable for unpaid personalized experimental treatment debt when the patient dies during treatment. Heirs also are not liable for lack of insurance caused by that treatment. This protection applies to those treatment-related debts and insurance consequences, not all debts the patient leaves behind.

Providers protected for recommending personalized treatment

Beginning July 1, 2025, licensing boards cannot punish providers solely for recommending personalized experimental treatment to an eligible patient. This includes suspending, revoking, or refusing to renew a license. Entities responsible for Medicare certification also cannot act against certification solely for that recommendation. The protection does not cover action based on other grounds.

Patients face treatment liability release requirements

Beginning July 1, 2025, required consent includes a treatment-related liability release for the treating provider, hospital, and manufacturers. The law creates no new private right to sue for treatment harm when a manufacturer or other care participant follows the law in good faith and uses reasonable care. This does not itself eliminate other existing rights to sue. Required health coverage for clinical trial participation remains unchanged.

Sponsors & Cosponsors

Sponsors

There is no primary sponsor on record.

Cosponsors

  • Janice Bowling

    Republican • Senate

  • Rusty Crowe

    Republican • Senate

  • Joey Hensley

    Republican • Senate

  • Becky D. Massey

    Republican • Senate

  • Reeves

    Affiliation unavailable

  • Paul Rose

    Republican • Senate

  • Stevens

    Affiliation unavailable

  • Page Walley

    Republican • Senate

  • Ken Yager

    Republican • Senate

Roll Call Votes

All Roll Calls

Yes: 121 • No: 7

Senate vote • 3/6/2025

FLOOR VOTE: as Amended Third Consideration 3/6/2025

Yes: 28 • No: 1

House vote • 3/6/2025

FLOOR VOTE: REGULAR CALENDAR PASSAGE ON THIRD CONSIDERATION 3/6/2025

Yes: 85 • No: 5

Senate vote • 2/26/2025

SENATE HEALTH AND WELFARE COMMITTEE

Yes: 8 • No: 1

Actions Timeline

  1. Effective date(s) 07/01/2025

    3/28/2025
  2. Pub. Ch. 45

    3/28/2025
  3. Signed by Governor.

    3/20/2025Senate
  4. Transmitted to Governor for action.

    3/12/2025Senate
  5. Signed by H. Speaker

    3/11/2025House
  6. Signed by Senate Speaker

    3/10/2025Senate
  7. Enrolled and ready for signatures

    3/7/2025Senate
  8. Sponsor(s) Added.

    3/6/2025Senate
  9. Passed H., Ayes 85, Nays 5, PNV 3

    3/6/2025House
  10. Subst. for comp. HB.

    3/6/2025House
  11. Engrossed; ready for transmission to House

    3/6/2025Senate
  12. Passed Senate as amended, Ayes 28, Nays 1, PNV 1

    3/6/2025Senate
  13. Senate adopted Amendment (Amendment 1 - SA0021)

    3/6/2025Senate
  14. Placed on Senate Regular Calendar for 3/6/2025

    3/4/2025Senate
  15. Sponsor(s) Added.

    3/3/2025Senate
  16. Sponsor(s) Added.

    2/26/2025Senate
  17. Recommended for passage with amendment/s, refer to Senate Calendar Committee Ayes 8, Nays 1 PNV 0

    2/26/2025Senate
  18. Placed on Senate Health and Welfare Committee calendar for 2/26/2025

    2/19/2025Senate
  19. Sponsor(s) Added.

    2/10/2025Senate
  20. Passed on Second Consideration, refer to Senate Health and Welfare Committee

    2/10/2025Senate
  21. Introduced, Passed on First Consideration

    1/27/2025Senate
  22. Filed for introduction

    1/24/2025Senate

Bill Text

  • Enrolled / Public Chapter

  • Fiscal Note

  • Introduced

  • SA0021

Related Bills

Back to State Legislation